.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DC10_Cefprozil.Cefprozil .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DC10_Cefprozil.Cefprozil| name: | Cefprozil |
| ATC code: | J01DC10 | route: | oral |
| n-compartments | 1 |
Cefprozil is a second-generation cephalosporin antibiotic, used to treat a variety of bacterial infections such as pharyngitis, tonsillitis, otitis media, skin and soft tissue infections, and respiratory tract infections. It is currently an approved antibiotic in various countries and is administered primarily via the oral route.
Pharmacokinetic parameters reported for healthy adult volunteers, both genders, after a single oral dose under fasting conditions.
Bathini, L, et al., & Garg, AX (2019). Clinical Outcomes of Failing to Dose-Reduce Cephalosporin Antibiotics in Older Adults with CKD. Clinical journal of the American Society of Nephrology : CJASN 14(2) 197–205. DOI:10.2215/CJN.10710918 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30630861
Kays, MB, et al., & Miles, DO (1999). In vitro activity and pharmacodynamics of oral beta-lactam antibiotics against Streptococcus pneumoniae from southeast Missouri. Pharmacotherapy 19(11) 1308–1314. DOI:10.1592/phco.19.16.1308.30869 PUBMED:https://pubmed.ncbi.nlm.nih.gov/10555936
Pichichero, ME, et al., & Nicolau, DP (2008). Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children. Paediatric drugs 10(6) 391–397. DOI:10.2165/0148581-200810060-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18998749